Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationFrancisco M. Marty, Cyrus Badshah, Per Ljungman et al.|New England Journal of Medicine|2017Cited by 1.2k
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical TrialRobin K. Avery, Sophie Alain, Barbara D. Alexander et al.|Clinical Infectious Diseases|2021Cited by 299
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott Goldsmith, Marcie Riches, Randy Taplitz et al.|Blood|2021Cited by 177
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections ForumPer Ljungman, Dana G. Wolf, Roy F. Chemaly et al.|Clinical Infectious Diseases|2024Cited by 145
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host diseaseEiko Hayase, Robert R. Jenq, Tomo Hayase et al.|Cell|2022Cited by 112